PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21915635-0	2012	Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5"-DFUR, the bioactive metabolite of Xeloda.	5"-dfur	138-145	epidermal growth factor receptor	Homo sapiens	14-18	
21915635-4	2012	Prior work in head and neck cancer showed that cell treatment with an inhibitor of the epidermal growth receptor (EGFR) gefitinib led to an increase in TP expression and sensitized them to 5"-DFUR.	5"-dfur	189-196	epidermal growth factor receptor	Homo sapiens	114-118	
23959266-6	2013	The observed synergy between gefitinib and 5"-DFUR has inspired the design of single molecules capable of acting as prodrugs of both an EGFR inhibitor and 5-FU.	5"-dfur	43-50	epidermal growth factor receptor	Homo sapiens	136-140	
23959266-12	2013	Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5"-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5"-DFUR.	5"-dfur	195-202	epidermal growth factor receptor	Homo sapiens	53-57	
23959266-12	2013	Our results in toto, suggest that capecitabine-based EGFR targeting combi-molecules of the same type than ZRX1, have the potential to induce stronger growth inhibitory potency than capecitabine, 5"-DFUR or single EGFR inhibitors and equivalent potency when compared with combinations of EGFR inhibitors + 5"-DFUR.	5"-dfur	305-312	epidermal growth factor receptor	Homo sapiens	53-57